Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
113 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2017 Summary Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 39 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 21 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Genetic Disorders, Ophthalmology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Multiple Myeloma (Kahler Disease), Breast Cancer, Myelodysplastic Syndrome, Diffuse Large B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Hematological Tumor, Inflammation, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atherosclerosis, Colorectal Cancer, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Alzheimer's Disease, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Burkitt Lymphoma, Carcinomas, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Lung Cancer, Malignant Pleural Mesothelioma, Melanoma, Metastatic Brain Tumor, Metastatic Liver Cancer, Nephropathy, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Pre-Diabetes/Impaired Glucose Tolerance, Renal Cell Carcinoma, Retinal Degeneration, Rheumatoid Arthritis, Small-Cell Lung Cancer, Substance (Drug) Abuse and Systemic Lupus Erythematosus. Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects - The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development Aptose Biosciences Inc Arvinas Inc AstraZeneca Plc ConverGene LLC Dybly AG F. Hoffmann-La Roche Ltd Forma Therapeutics Inc GlaxoSmithKline Plc Incyte Corp Kainos Medicine Inc Merck & Co Inc Nuevolution AB Plexxikon Inc Resverlogix Corp Trillium Therapeutics Inc Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles apabetalone - Drug Profile Product Description Mechanism Of Action R&D Progress ARCC-29 - Drug Profile Product Description Mechanism Of Action R&D Progress ARV-763 - Drug Profile Product Description Mechanism Of Action R&D Progress ARV-771 - Drug Profile Product Description Mechanism Of Action R&D Progress ARV-825 - Drug Profile Product Description Mechanism Of Action R&D Progress AZD-5153 - Drug Profile Product Description Mechanism Of Action R&D Progress birabresib - Drug Profile Product Description Mechanism Of Action R&D Progress CG-202 - Drug Profile Product Description Mechanism Of Action R&D Progress CG-223 - Drug Profile Product Description Mechanism Of Action R&D Progress CG-250 - Drug Profile Product Description Mechanism Of Action R&D Progress CK-103 - Drug Profile Product Description Mechanism Of Action R&D Progress CPI-0610 - Drug Profile Product Description Mechanism Of Action R&D Progress DCBD-005 - Drug Profile Product Description Mechanism Of Action R&D Progress DYB-186 - Drug Profile Product Description Mechanism Of Action R&D Progress EP-11313 - Drug Profile Product Description Mechanism Of Action R&D Progress FT-1101 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-525762 - Drug Profile Product Description Mechanism Of Action R&D Progress INCB-54329 - Drug Profile Product Description Mechanism Of Action R&D Progress KM-601 - Drug Profile Product Description Mechanism Of Action R&D Progress MA-2014 - Drug Profile Product Description Mechanism Of Action R&D Progress MS-417 - Drug Profile Product Description Mechanism Of Action R&D Progress MZ-1 - Drug Profile Product Description Mechanism Of Action R&D Progress NEO-2734 - Drug Profile Product Description Mechanism Of Action R&D Progress NUE-7770 - Drug Profile Product Description Mechanism Of Action R&D Progress PLX-51107 - Drug Profile Product Description Mechanism Of Action R&D Progress RG-6146 - Drug Profile Product Description Mechanism Of Action R&D Progress RVX-2135 - Drug Profile Product Description Mechanism Of Action R&D Progress S-10 - Drug Profile Product Description Mechanism Of Action R&D Progress SF-2523 - Drug Profile Product Description Mechanism Of Action R&D Progress SF-2535 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Bromodomain Containing Protein-4 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit BRD4 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit BRD4 for Ovarian Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress SRX-3177 - Drug Profile Product Description Mechanism Of Action R&D Progress TTI-281 - Drug Profile Product Description Mechanism Of Action R&D Progress ZBC-260 - Drug Profile Product Description Mechanism Of Action R&D Progress ZEN-3694 - Drug Profile Product Description Mechanism Of Action R&D Progress Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones Featured News & Press Releases Jun 05, 2017: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017 Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention May 31, 2017: Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain May 30, 2017: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone May 23, 2017: Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success May 15, 2017: Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial May 01, 2017: SignalRx Discloses its Novel Immuno-Oncology Program Approach at the 12th Annual Drug Discovery Chemistry 2017 Meeting Apr 25, 2017: SignalRx to Present at the 12th Annual Drug Discovery Chemistry 2017 Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer Apr 03, 2017: SignalRx to Present at the AACR Annual Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer Mar 17, 2017: Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities Mar 15, 2017: Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office Feb 23, 2017: Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial Feb 13, 2017: Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy and Neurodegenerative Eye Disease Feb 01, 2017: SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication Jan 23, 2017: Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Aptose Biosciences Inc, H1 2017 Pipeline by Arvinas Inc, H1 2017 Pipeline by AstraZeneca Plc, H1 2017 Pipeline by ConverGene LLC, H1 2017 Pipeline by Dybly AG, H1 2017 Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Pipeline by Forma Therapeutics Inc, H1 2017 Pipeline by GlaxoSmithKline Plc, H1 2017 Pipeline by Incyte Corp, H1 2017 Pipeline by Kainos Medicine Inc, H1 2017 Pipeline by Merck & Co Inc, H1 2017 Pipeline by Nuevolution AB, H1 2017 Pipeline by Plexxikon Inc, H1 2017 Pipeline by Resverlogix Corp, H1 2017 Pipeline by Trillium Therapeutics Inc, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
